The start-up is developing a novel treatment that aims to be an alternative to surgical interventions in cases of TGCT, a rare type of tumour that reduces mobility. : Dublin and Oxford-based SynOx raises $75m in Series B Read this story
The start-up is developing a novel treatment that aims to be an alternative to surgical interventions in cases of TGCT, a rare type of tumour that reduces mobility. : Dublin and Oxford-based SynOx raises $75m in Series B Read this story
More from Silicon Republic | Start-ups entrepreneurs funding and investment health medicine pharma UK